Page last updated: 2024-09-05

sorafenib and Sensitivity and Specificity

sorafenib has been researched along with Sensitivity and Specificity in 35 studies

Research

Studies (35)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	10 (28.57)	29.6817
2010's	23 (65.71)	24.3611
2020's	2 (5.71)	2.80

Authors

Authors	Studies
Luo, C; Marmorstein, R; Xie, P	1
Chao, YS; Chen, CH; Chen, CP; Chen, CT; Chiu, CH; Chou, LH; Hsieh, SY; Hsu, JT; Hsu, T; Jiaang, WT; Lin, WH; Lu, CT; Song, JS; Tseng, YJ; Yang, YN; Yeh, CF; Yeh, TK; Yen, KJ; Yen, SC	1
Bharatam, PV; Johnsirani, P; Nanjappan, S; Wani, AA	1
Chen, Y; Jiang, L; Lei, J; Li, Y; Peng, J; Sheng, H; Wang, J; Wu, L; Xu, Y; Yu, H; Zhang, J; Zhang, X; Zhao, H; Zhou, Y	1
Allard, M; Blanchet, B; Costentin, C; Hulin, A; Joly, C; Khoudour, N; Rousseau, B; Tournigand, C	1
Cho, NP; Cho, SD; Hong, IS; Jung, JY; Nam, JS; Shin, JA; Yu, HJ	1
Götze, L; Hegele, A; Hofmann, R; Keil, C; Nockher, WA; Olbert, P	1
Im, GH; Jeon, TY; Kim, CK; Kim, JH; Lee, JH; Park, BK	1
Moriyasu, F; Saito, K; Shirota, N; Sugimoto, K; Takara, K; Tokuuye, K	1
Ameye, L; Delaunoit, T; Deleporte, A; Demolin, G; Flamen, P; Garcia, C; Gauthier, N; Guiot, T; Hendlisz, A; Holbrechts, S; Lhommel, R; Maréchal, R; Van den Eynde, M; Vierasu, I; Woff, E	1
Fu, CX; Gao, DM; Han, ZH; Lin, J; Liu, H; Lu, F; Lv, P; Yang, SH	1
Chen, X; He, L; Huang, Y; Liang, C; Liu, Z; Ma, Z; Shi, C; Zhang, Z	1
Adjei, AA	1
Carroll, S; Dale, P; Knox, J; Maroun, J; McDonald, H; Muszbek, N; Shah, S	1
Beijnen, JH; Lagas, JS; Schellens, JH; Schinkel, AH; Sparidans, RW; Vlaming, ML	1
Aziz, SA; Camp, RL; Conrad, PJ; Jilaveanu, LB; Kluger, HM; Rimm, DL; Schmitz, JC; Sznol, M; Zito, CR	1
Bitzer, M; Claussen, CD; Horger, M; Lauer, U; Martirosian, P; Schraml, C; Schwenzer, NF	1
Bitzer, M; Claussen, CD; Hartmann, JT; Horger, M; Maksimovic, O; Pintoffl, J; Schraml, C	1
Lieber, ML; Shah, SN; Smith, AD	1
Kudo, M	1
Lieber, ML; Remer, EM; Rini, BI; Shah, SN; Smith, AD	1
Akisik, MF; Bu, G; Chiorean, EG; Hutchins, GD; Lin, C; Sandrasegaran, K	1
Balvay, D; Banu, E; Chatellier, G; Cuenod, CA; Fournier, LS; Frija, G; Medioni, J; Oudard, S; Thiam, R; Trinquart, L	1
de Ruysscher, D; Dingemans, AM; Lind, JS; Meijerink, MR; Ollers, MC; Postmus, PE; Smit, EF; van Kuijk, C	1
Arrivé, L; Fartoux, L; Lewin, M; Menu, Y; Rosmorduc, O; Vignaud, A	1
Heinz, WJ; Helle-Beyersdorf, A; Kahle, K; Keller, D; Klinker, H; Langmann, P; Lenker, U; Schirmer, D	1
Bruns, CJ; Clevert, DA; Cyran, CC; Dietrich, O; Eschbach, R; Hinkel, R; Ingrisch, M; Nikolaou, K; Paprottka, PM; Reiser, MF; Schwarz, B; von Einem, JC; Wintersperger, BJ	1
Chatzimichail, K; Gkoutzios, P; Kalokairinou, M; Karagiannis, E; Kiltenis, M; Kornezos, I; Malagari, K; Moschouris, H; Papadaki, MG; Stamatiou, K	1
Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ	1
Dai, X; Ganten, MK; Ganten, TM; Höh, K; Schlemmer, HP; Schmidt, B; Xu, K	1
Frampas, E; Koscielny, S; Lassau, N; Vilgrain, V; Vullierme, MP; Zappa, M	1
Afify, S; Högger, P; Rapp, UR	1
Beeram, M; Patnaik, A; Rowinsky, EK	1
Baker, SD; Hafner, FT; He, P; Hidalgo, M; Messersmith, WA; Radtke, M; Rudek, MA; Smith, BD; Wright, JJ; Zhao, M	1
Dahut, W; Figg, WD; Gardner, ER; Jain, L; Venitz, J	1

Reviews

2 review(s) available for sorafenib and Sensitivity and Specificity

Article	Year
K-ras as a target for lung cancer therapy. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:6 Suppl 2 Topics: Benzamides; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sensitivity and Specificity; Sorafenib; Survival Analysis; Treatment Outcome	2008
Raf: a strategic target for therapeutic development against cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-20, Volume: 23, Issue:27 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Down-Regulation; Drug Delivery Systems; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Biology; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; raf Kinases; Sensitivity and Specificity; Signal Transduction; Sorafenib	2005

Article

Year

K-ras as a target for lung cancer therapy.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008, Volume: 3, Issue:6 Suppl 2

Topics: Benzamides; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Delivery Systems; Drugs, Investigational; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Risk Factors; Sensitivity and Specificity; Sorafenib; Survival Analysis; Treatment Outcome

2008

Raf: a strategic target for therapeutic development against cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Sep-20, Volume: 23, Issue:27

Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Down-Regulation; Drug Delivery Systems; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Biology; Mutation; Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins A-raf; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; raf Kinases; Sensitivity and Specificity; Signal Transduction; Sorafenib

2005

Trials

9 trial(s) available for sorafenib and Sensitivity and Specificity

Article	Year
[Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib]. Der Urologe. Ausg. A, 2015, Volume: 54, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Renal Cell; Drug Monitoring; Feasibility Studies; Female; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sulfonamides; Sunitinib	2015
Monitoring metabolic response using FDG PET-CT during targeted therapy for metastatic colorectal cancer. European journal of nuclear medicine and molecular imaging, 2016, Volume: 43, Issue:10 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Drug Monitoring; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome	2016
Economic evaluation of sorafenib in the treatment of hepatocellular carcinoma in Canada. Current medical research and opinion, 2008, Volume: 24, Issue:12 Topics: Antineoplastic Agents; Benzenesulfonates; Canada; Carcinoma, Hepatocellular; Disease-Free Survival; Europe; Humans; Liver Neoplasms; Markov Chains; Models, Theoretical; Niacinamide; Phenylurea Compounds; Pyridines; Sensitivity and Specificity; Sorafenib; Survival Rate	2008
Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology, 2010, Volume: 256, Issue:2 Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Contrast Media; Female; Gadolinium DTPA; Humans; Image Enhancement; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome	2010
Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT. Radiology, 2010, Volume: 256, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome	2010
Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? European radiology, 2010, Volume: 20, Issue:12 Topics: Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Contrast Media; Erlotinib Hydrochloride; Female; Humans; Iohexol; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Quinazolines; Radiographic Image Enhancement; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome	2010
Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography. Medical ultrasonography, 2012, Volume: 14, Issue:2 Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Liver Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Ultrasonography	2012
Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib. European journal of radiology, 2013, Volume: 82, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Female; Humans; Imaging, Three-Dimensional; Iopamidol; Liver Neoplasms; Male; Middle Aged; Niacinamide; Outcome Assessment, Health Care; Phenylurea Compounds; Pilot Projects; Radiography, Dual-Energy Scanned Projection; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome	2013
Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results. European journal of radiology, 2013, Volume: 82, Issue:5 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Female; Humans; Indoles; Liver Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Niacinamide; Perfusion Imaging; Phenylurea Compounds; Pilot Projects; Prognosis; Pyrroles; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography	2013

Other Studies

24 other study(ies) available for sorafenib and Sensitivity and Specificity

Article	Year
Identification of BRAF inhibitors through in silico screening. Journal of medicinal chemistry, 2008, Oct-09, Volume: 51, Issue:19 Topics: Algorithms; Binding Sites; Cloning, Molecular; Computer Simulation; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Models, Chemical; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Sensitivity and Specificity; Small Molecule Libraries; Stereoisomerism; Structure-Activity Relationship	2008
Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3). Bioorganic & medicinal chemistry, 2013, Jun-01, Volume: 21, Issue:11 Topics: Animals; Antineoplastic Agents; Benzamides; Cell Line, Tumor; Cell Proliferation; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Mice; Protein Kinase Inhibitors; Sensitivity and Specificity; Structure-Activity Relationship; Urea; Xenograft Model Antitumor Assays	2013
LC-ESI-QTOF-MS analysis utilizing gas-phase fragmentation reactions subjected to ESI-IS-CID and ESI-CID-MS/MS conditions to study the degradation behaviour of sorafenib tosylate: NMR and in vitro cytotoxicity and apoptosis detection studies of hydrolytic Journal of pharmaceutical and biomedical analysis, 2020, Jan-05, Volume: 177 Topics: Antineoplastic Agents; Apoptosis; Cell Survival; Chemistry, Pharmaceutical; Chromatography, High Pressure Liquid; Drug Stability; Drug Storage; Hep G2 Cells; Humans; Hydrolysis; Inhibitory Concentration 50; Limit of Detection; Magnetic Resonance Spectroscopy; Sensitivity and Specificity; Sorafenib; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry	2020
Microbiota-derived SSL6 enhances the sensitivity of hepatocellular carcinoma to sorafenib by down-regulating glycolysis. Cancer letters, 2020, 07-01, Volume: 481 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; CD47 Antigen; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Exotoxins; Glycolysis; Hep G2 Cells; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Microbiota; Phosphatidylinositol 3-Kinases; Sensitivity and Specificity; Sorafenib; Xenograft Model Antitumor Assays	2020
Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS. Journal of pharmaceutical and biomedical analysis, 2017, Aug-05, Volume: 142 Topics: Chromatography, Liquid; Humans; Niacinamide; Phenylurea Compounds; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tandem Mass Spectrometry	2017
Inhibition of myeloid cell leukemia-1: Association with sorafenib-induced apoptosis in human mucoepidermoid carcinoma cells and tumor xenograft. Head & neck, 2015, Volume: 37, Issue:9 Topics: Animals; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Cell Proliferation; Disease Models, Animal; Down-Regulation; Female; Heterografts; Humans; Mice; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Random Allocation; Real-Time Polymerase Chain Reaction; RNA, Small Interfering; Salivary Gland Neoplasms; Sensitivity and Specificity; Signal Transduction; Sorafenib; Tumor Cells, Cultured	2015
Assessment of early therapeutic response to sorafenib in renal cell carcinoma xenografts by dynamic contrast-enhanced and diffusion-weighted MR imaging. The British journal of radiology, 2015, Volume: 88, Issue:1053 Topics: Animals; Biomarkers, Tumor; Carcinoma, Renal Cell; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Models, Animal; Feasibility Studies; Kidney Neoplasms; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Prognosis; Protein Kinase Inhibitors; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome	2015
Intravoxel incoherent motion MRI as a biomarker of sorafenib treatment for advanced hepatocellular carcinoma: a pilot study. Cancer imaging : the official publication of the International Cancer Imaging Society, 2016, Jan-29, Volume: 16 Topics: Aged; Algorithms; Antineoplastic Agents; Biomarkers; Carcinoma, Hepatocellular; Contrast Media; Diffusion Magnetic Resonance Imaging; Disease Progression; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Male; Middle Aged; Multidetector Computed Tomography; Niacinamide; Phenylurea Compounds; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; raf Kinases; Remission Induction; Sensitivity and Specificity; Sorafenib; Treatment Outcome	2016
Evaluation of antiangiogenic and antiproliferative effects of sorafenib by sequential histology and intravoxel incoherent motion diffusion-weighted imaging in an orthotopic hepatocellular carcinoma xenograft model. Journal of magnetic resonance imaging : JMRI, 2017, Volume: 45, Issue:1 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Diffusion Magnetic Resonance Imaging; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Angiography; Male; Mice; Mice, Inbred BALB C; Motion; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome	2017
Multiparametric MR diffusion-weighted imaging for monitoring the ultra-early treatment effect of sorafenib in human hepatocellular carcinoma xenografts. Journal of magnetic resonance imaging : JMRI, 2017, Volume: 46, Issue:1 Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Drug Monitoring; Early Detection of Cancer; Female; Humans; Image Interpretation, Computer-Assisted; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Multimodal Imaging; Niacinamide; Phenylurea Compounds; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome	2017
Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2009, Jan-15, Volume: 877, Issue:3 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Chromatography, Liquid; Female; Glucuronides; Liver; Male; Mice; Niacinamide; Phenylurea Compounds; Pilot Projects; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Tandem Mass Spectrometry	2009
C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Sep-15, Volume: 15, Issue:18 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cohort Studies; Disease Progression; Female; Gene Silencing; Humans; Indoles; Male; Melanoma; Middle Aged; Nevus; Niacinamide; Phenols; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Pyridines; RNA, Small Interfering; Sensitivity and Specificity; Skin Neoplasms; Sorafenib; Young Adult	2009
Diffusion-weighted MRI of advanced hepatocellular carcinoma during sorafenib treatment: initial results. AJR. American journal of roentgenology, 2009, Volume: 193, Issue:4 Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prognosis; Pyridines; Sensitivity and Specificity; Sorafenib; Treatment Outcome	2009
Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR. American journal of roentgenology, 2010, Volume: 194, Issue:1 Topics: Adrenal Gland Neoplasms; Aged; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Contrast Media; Female; Humans; Kidney Neoplasms; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Pheochromocytoma; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography	2010
Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT. AJR. American journal of roentgenology, 2010, Volume: 194, Issue:1 Topics: Adult; Aged; Analysis of Variance; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome	2010
The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. Journal of gastroenterology and hepatology, 2010, Volume: 25, Issue:3 Topics: Algorithms; alpha-Fetoproteins; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Biomarkers, Tumor; Carcinoma, Hepatocellular; Contrast Media; Early Detection of Cancer; Gadolinium DTPA; Humans; Infusion Pumps; Japan; Liver Neoplasms; Magnetic Resonance Imaging; Mass Screening; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Population Surveillance; Protein Precursors; Prothrombin; Pyridines; Sensitivity and Specificity; Sorafenib; Survival Rate	2010
Morphology, Attenuation, Size, and Structure (MASS) criteria: assessing response and predicting clinical outcome in metastatic renal cell carcinoma on antiangiogenic targeted therapy. AJR. American journal of roentgenology, 2010, Volume: 194, Issue:6 Topics: Adult; Aged; Angiogenesis Inhibitors; Benzenesulfonates; Carcinoma, Renal Cell; Contrast Media; Disease Progression; Female; Humans; Indoles; Iohexol; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Retrospective Studies; Sensitivity and Specificity; Sorafenib; Sunitinib; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome	2010
The diffusion-weighted imaging perfusion fraction f is a potential marker of sorafenib treatment in advanced hepatocellular carcinoma: a pilot study. European radiology, 2011, Volume: 21, Issue:2 Topics: Aged; Algorithms; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Diffusion Magnetic Resonance Imaging; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Liver Neoplasms; Magnetic Resonance Angiography; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Pilot Projects; Prognosis; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Treatment Outcome	2011
High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid. Cancer chemotherapy and pharmacology, 2011, Volume: 68, Issue:1 Topics: Antineoplastic Agents; Ascitic Fluid; Benzenesulfonates; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Chromatography, High Pressure Liquid; Drug Monitoring; Humans; Kidney Neoplasms; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Sensitivity and Specificity; Sorafenib	2011
Dynamic contrast-enhanced computed tomography imaging biomarkers correlated with immunohistochemistry for monitoring the effects of sorafenib on experimental prostate carcinomas. Investigative radiology, 2012, Volume: 47, Issue:1 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers; Cell Line, Tumor; Contrast Media; Iohexol; Male; Niacinamide; Phenylurea Compounds; Prostatic Neoplasms; Pyridines; Rats; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Statistics as Topic; Tomography, X-Ray Computed; Treatment Outcome	2012
Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma. The Journal of urology, 2013, Volume: 190, Issue:1 Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dietary Supplements; Disease Models, Animal; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Hymecromone; Immunoblotting; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Random Allocation; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2013
Validation of a liquid chromatography assay for the quantification of the Raf kinase inhibitor BAY 43-9006 in small volumes of mouse serum. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2004, Sep-25, Volume: 809, Issue:1 Topics: Animals; Benzenesulfonates; Calibration; Enzyme Inhibitors; Mice; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-raf; Pyridines; Reproducibility of Results; Sensitivity and Specificity; Sorafenib	2004
A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2007, Feb-01, Volume: 846, Issue:1-2 Topics: Area Under Curve; Benzenesulfonates; Calibration; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sorafenib; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry	2007
Development of a rapid and sensitive LC-MS/MS assay for the determination of sorafenib in human plasma. Journal of pharmaceutical and biomedical analysis, 2008, Jan-22, Volume: 46, Issue:2 Topics: Benzenesulfonates; Calibration; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Reference Standards; Reproducibility of Results; Sensitivity and Specificity; Sorafenib	2008